KCKyle Carson

Kyle Carson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kyle Carson has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Detection of COVID-19-Related Multivariate Biomarker Immune Response in Pediatric Patients: Statistical Aspects

    by Michael Brimacombe, Aishwarya Jadhav, David A. Lawrence, Kyle Carson, William T. Lee, Alexander H. Hogan, Katherine W. Herbst, Michael A. Lynes, Juan C. Salazar

    The development of new point-of-care diagnostic testing tools for the detection of infectious diseases such as COVID-19 are a key aspect of clinical care and research. Accurate predictive classification methods are required to correctly identify and treat patients. Here, the onset of multisystem inflammatory syndrome in children (MIS-C), a more serious form of COVID-19, was predicted in a pediatric population using a set of multivariate immunological biomarker expression values. A first-stage bivariate detection of statistically significant biomarkers was obtained from a chosen set of standard cytokines and chemokine biomarkers considered relevant to COVID-19-related infection and disease. To incorporate the observed correlation structure among the resulting set of significant biomarkers, dimension reduction was then applied in the form of principal components. A second-stage logistic regression model using a small number of the principal component variables provided a highly predictive classification model for MIS-C. The resulting model was shown to compare favorably with an artificial neural network-based predictive model.


  • Open Access

    Inflammatory and Autoimmune Aspects of Multisystem Inflammatory Syndrome in Children (MIS-C): A Prospective Cohort Study

    by David A. Lawrence, Aishwarya Jadhav, Tapan K. Mondal, Kyle Carson, William T. Lee, Alexander H. Hogan, Katherine W. Herbst, Ian C. Michelow, Michael Brimacombe, Juan C. Salazar, et al.

    Multisystem Inflammatory Syndrome in Children (MIS-C) is a potentially life-threatening complication of COVID-19. The pathophysiological mechanisms leading to severe disease are poorly understood. This study leveraged clinical samples from a well-characterized cohort of children hospitalized with COVID-19 or MIS-C to compare immune-mediated biomarkers. Our objective was to identify selected immune molecules that could explain, in part, why certain SARS-CoV-2-infected children developed MIS-C. We hypothesized that type-2 helper T cell-mediated inflammation can elicit autoantibodies, which may account for some of the differences observed between the moderate–severe COVID-19 (COVID+) and MIS-C cohort. We enumerated blood leukocytes and measured levels of selected serum cytokines, chemokines, antibodies to COVID-19 antigens, and autoantibodies in children presenting to an academic medical center in Connecticut, United States. The neutrophil/lymphocyte and eosinophil/lymphocyte ratios were significantly higher in those in the MIS-C versus COVID+ cohort. IgM and IgA, but not IgG antibodies to SARS-CoV-2 receptor binding domain were significantly higher in the MIS-C cohort than the COVID+ cohort. The serum levels of certain type-2 cytokines (interleukin (IL)-4, IL-5, IL-6, IL-8, IL-10, IL-13, and IL-33) were significantly higher in children with MIS-C compared to the COVID+ and SARS-CoV-2-negative cohorts. IgG autoantibodies to brain antigens and pentraxin were higher in children with MIS-C compared to SARS-CoV-19-negative controls, and children with MIS-C had higher levels of IgG anti-contactin-associated protein-like 2 (caspr2) compared to the COVID+ and SARS-CoV-19-negative controls. We speculate that autoimmune responses in certain COVID-19 patients may induce pathophysiological changes that lead to MIS-C. The triggers of autoimmunity and factors accounting for type-2 inflammation require further investigation.


  • Open Access

    Serological Analysis Reveals an Imbalanced IgG Subclass Composition Associated with COVID-19 Disease Severity

    by Jennifer L. Yates, Dylan J. Ehrbar, Danielle T. Hunt, Roxanne C. Girardin, Alan Dupuis, Anne F. Payne, Mycroft Sowizral, Scott Varney, Karen E. Kulas, Valerie L. Demarest, et al.

    Summary: COVID-19 is associated with a wide spectrum of disease severity, ranging from asymptomatic to acute respiratory distress syndrome (ARDS). Paradoxically, a direct relationship has been suggested between COVID-19 disease severity, and the levels of circulating SARS-CoV-2-specific antibodies, including virus neutralizing titers. Through a serological analysis of serum samples from 536 convalescent healthcare workers, we found that SARS-CoV-2-specific and virus-neutralizing antibody levels were indeed elevated in individuals that experienced severe disease. The severity-associated increase in SARS-CoV-2-specific antibody was dominated by IgG, with an IgG subclass ratio skewed towards elevated receptor binding domain (RBD)- and S1-specific IgG3. However, RBD- and S1-specific IgG1, rather than IgG3 were best correlated with virus-neutralizing titers. We propose that Spike-specific IgG3 subclass utilization contributes to COVID-19 disease severity through potent Fc-mediated effector functions . These results have significant implications for SARS-CoV-2 vaccine design, and convalescent plasma therapy.